Review
Published on 26 Jun 2025
Oxidative stress in ARDS: mechanisms and therapeutic potential
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1603287
- 185 views
Type at least 3 characters
626 articles
Original Research
Published on 25 Jun 2025
Role and mechanism of IGFBP5 in the real-ambient particulate matter exposure-induced chronic lung injury
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1604301
- 195 views
Case Report
Published on 25 Jun 2025
Case Report: Polymyxin B-induced anaphylactic shock
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1594127
- 167 views
Editorial
Accepted on 19 Jun 2025
Editorial: Use of Bioactives for Treatment of Respiratory Diseases
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1630486
Original Research
Published on 19 Jun 2025
Drug-related problems in elderly patients with AECOPD and pharmaceutical intervention practice: a prospective study
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1596795
- 362 views
Original Research
Published on 18 Jun 2025
Oral Angiotensin-(1-7) formulation after established elastase-induced emphysema suppresses inflammation and restores lung architecture
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1540475
- 380 views
Original Research
Accepted on 16 Jun 2025
EPA-Lactone derivative, 5,6-diHETE lactone, improves pulmonary arterial hypertension in a monocrotaline-induced model
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1621030
- 137 views
Original Research
Accepted on 16 Jun 2025
Novel mitophagy inducer TJ0113 alleviates pulmonary inflammation during acute lung injury
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1590458
- 118 views
Original Research
Published on 13 Jun 2025
Clinical features and genetic spectrum of children with primary ciliary dyskinesia in central China: a referral center retrospective analysis
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1526675
- 424 views
Case Report
Accepted on 11 Jun 2025
Omalizumab Combined with Voriconazole for the Treatment of ABPA Complicating IPA: A Case Report
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1588182
- 200 views
Editorial
Published on 11 Jun 2025
Editorial: Applications of AI, machine learning, computational medicine, and bioinformatics in respiratory pharmacology
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1602941
- 846 views
Original Research
Published on 05 Jun 2025
Machine learning-based prediction model for lung ischemia-reperfusion injury: insights from disulfidptosis-related genes
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1545111
- 566 views
Original Research
Published on 05 Jun 2025
Real-world treatment persistence and predictive factors for discontinuation of antifibrotic therapies in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of two multicenter observational cohort studies in Poland
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1586197
- 908 views
Original Research
Published on 30 May 2025
Efficacy and safety of a new drug formulation, amoxicillin-clavulanate-cineole, for adult lower respiratory tract infections: a nationwide observational study in Morocco
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1549014
- 660 views
Original Research
Published on 30 May 2025
D-cycloserine effects on COPD and depression in a murine experimental model
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1554337
- 506 views
Review
Published on 30 May 2025
Current advancements in the mechanisms and animal models of acute exacerbation of pulmonary fibrosis: a systematic review
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1501085
- 849 views